MedWorm: Pravastatin

PRAVASTATIN SODIUMtablet [International Labs, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 07 Feb 2012 05:00:00 +0100

Updated Date: Feb 7, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Direct to consumer Internet advertising of statins: an assessment of safety

Pharmacoepidemiology and Drug Safety — Thu, 02 Feb 2012 05:00:00 +0100

ConclusionsA potential purchaser of statins is likely to encounter websites from a wide geographical base and of generally poor quality. This has potentially serious implications for the safety of purchasers who may not be aware of the problems associated with ordering medicines online or the actual medication, which they receive. Direct to consumer advertising websites need tighter controls. Copyright © 2012 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)

Pitavastatin beats pravastatin at improving albuminuria in diabetes

MedWire News - Diabetes — Thu, 02 Feb 2012 00:00:00 +0100

Pitavastatin is more effective than pravastatin at reducing albuminuria in Type 2 diabetes patients with early-stage diabetic nephropathy, show study findings. (Source: MedWire News - Diabetes)

PRAVASTATIN SODIUMtablet [Cobalt Laboratories Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 01 Feb 2012 05:00:00 +0100

Updated Date: Feb 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis

American Heart Journal — Wed, 01 Feb 2012 05:00:00 +0100

Conclusions: Both pitavastatin and pravastatin altered coronary artery plaque composition by significantly decreasing the fibrofatty plaque component and increasing the calcified plaque component. (Source: American Heart Journal)

Anastrozole/pravastatin: Liver injury in an elderly patient: case report

Reactions — Mon, 23 Jan 2012 18:35:21 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy

Diabetes, Obesity and Metabolism — Mon, 23 Jan 2012 05:00:00 +0100

The effect of pitavastatin and pravastatintreatment on renal function was compared in type 2 diabetes patients with nephropathy in a randomized, controlled, open‐label, parallel and multi‐center study.Type 2 diabetic patients with modest renal impairment (serum creatinine level<1.4 mg/dL) accompanied by albuminuria (30‐600mg/g creatinine) were randomly assigned to receive 2 mg of pitavastatin (n = 44) or 10 mg of pravastatin (n =43) for 12 months. At 12 months,pitavastatin significantly reduced urinary albumin‐to‐creatinine ratio than pravastatin in subjects with macroalbuminuria (‐67.2 % vs. +14.5%,P = 0.0040), but not in subjects with microalbuminuria. There was no significant difference in the change in estimated glomerular filtration rate (eGFR)between two groups.Pitavas...

Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking

Computers in Biology and Medicine — Sun, 22 Jan 2012 03:06:38 +0100

This study was designed to understand the mode of interactions of HMGCR isoform 2 with other statins. Hence, ligands such as Atorvastatin (DB01076), Lovastatin (DB00227), Fluvastatin (DB01095), Simvastatin (DB00641), Pravastatin (DB00175), Rosuvastatin (DB01098) and Cerivastatin (DB00439) were docked with enzymes HMGCR isoform 1 (pdb: 1DQ8) and modeled HMGCR isoform 2 (gi|196049380). Our homology modeling results were further processed to model the structure of human HMGCR isoform 2 and its accuracy was confirmed through RMS Z-scores (1.249). These interactions revealed that binding residues such as Arg515, Asp516, Tyr517 and Asn518 are found to be conserved in HMGCR isoform 2 with various statins. Our studies further concluded that Atorvastatin is most efficient inhibitor against both the...

Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis

QJM — Mon, 16 Jan 2012 05:00:00 +0100

Discussion: Although statins are generally well tolerated, there are risks associated with almost all drugs. With few exceptions, statins appear to exert a similar risk across individual drugs. (Source: QJM)

Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells

Clinical and Experimental Immunology — Thu, 12 Jan 2012 05:00:00 +0100

SummaryStatins are 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitors of cholesterol biosynthesis, and they have been reported to exert pleiotropic effects on cellular signaling and cellular functions involved in inflammation. Recent reports demonstrated that prior statin therapy reduced the risk of pneumonia or increased survival in patients with community‐acquired pneumonia. However, the precise mechanisms responsible for these effects are unclear. In the present study, we examined the effects of statins on cytokine production from lipopolysaccharide (LPS)‐stimulated human bronchial epithelial cells (BEAS‐2B). Interleukin (IL)‐6 and IL‐8 mRNA expression and protein secretion in LPS‐stimulated cells were significantly inhibited by the lipophilic statin pitavast...

Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk.

The Journal of Clinical Endocrinology and Metabolism — Wed, 11 Jan 2012 05:00:00 +0100

Conclusion:Older people at high cardiovascular risk with low or very high TSH along with normal free T(4) appear at increased risk of incident heart failure. PMID: 22238391 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

MedWorm Sponsor Message: Find the best January Sales in the UK.

The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin

British Journal of Clinical Pharmacology — Sun, 08 Jan 2012 18:02:42 +0100

CONCLUSION The rs4149056 SNP did not significantly affect the pharmacodynamics of pravastatin. (Source: British Journal of Clinical Pharmacology)

EPR studies on hydroxyl radical-scavenging activities of pravastatin and fluvastatin.

Molecular and Cellular Biochemistry — Fri, 30 Dec 2011 05:00:00 +0100

In this study, electron paramagnetic resonance spectroscopy in combination with 5,5-dimethyl-1-pyrroline N-oxide (DMPO)-spin-trapping technique was utilized to determine the abilities of pravastatin and fluvastatin in scavenging hydroxyl radical generated from Fe(II) with H(2)O(2) system. In addition, we examined the effects of pravastatin and fluvastatin on oxidative-induced φX-174 RF I plasmid DNA damage. We have demonstrated here for the first time that pravastatin and fluvastatin at physiologically relevant concentrations significantly decreased formation of DMPO-OH adduct indicating that both compounds could directly scavenge hydroxyl radicals. However, pravastatin and fluvastatin were not able to directly protect against oxidative DNA plasmid damage. The hydroxyl radical sequesterin...

Pravastatin normalizes EDCF‐mediated response via suppression of Rho‐kinase signalling in mesenteric artery from aged type 2 diabetic rat

Acta Physiologica — Thu, 29 Dec 2011 15:42:11 +0100

ConclusionsThese results suggest that pravastatin exerts beneficial effects against abnormal EDCF signalling by suppressing Rho‐kinase and promoting antioxidant activity in the mesenteric arteries of rats at the chronic stage of type 2 diabetes. (Source: Acta Physiologica)

Pravastatin normalizes endothelium‐derived contracting factor‐mediated response via suppression of Rho‐kinase signalling in mesenteric artery from aged type 2 diabetic rat

Acta Physiologica — Wed, 28 Dec 2011 05:00:00 +0100

Conclusions:These results suggest that pravastatin exerts beneficial effects against abnormal EDCF signalling by suppressing Rho‐kinase and promoting antioxidant activity in the mesenteric arteries of rats at the chronic stage of type 2 diabetes. (Source: Acta Physiologica)

KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly

Atherosclerosis — Fri, 23 Dec 2011 05:00:00 +0100

We examined SNPs at the KIF6 (rs20455 or 719Arg), LPA (rs3798220), TAS2R50 (rs1376251) and VAMP8 (rs1010) in 5,411 participants in PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) (mean age 75.3 years), who had been randomized to pravastatin 40mg/day or placebo and were followed for a mean of 3.2 years. No SNP was related to vascular disease at baseline. Only the KIF6 SNP was related to LDL-C lowering with homozygous Arg 719 subjects being significantly less responsive than other groups (p=0.025, −34.2 vs. −36.1%). With regard to the primary CHD endpoint on trial (fatal or non-fatal myocardial infarction or stroke), we observed a significant relationship for KIF6 719Arg homozygotes (p=0.03, hazards ratio 0.47, 12.8% of the population) in women on pravastatin only, and ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly

Atherosclerosis — Wed, 21 Dec 2011 05:00:00 +0100

We examined associations of single nucleotide polymorphisms (SNPs) at the liver X receptor alpha (LXRA, rs12221497), and the solute carrier organic anion transporter (SLCO1B1, rs4149056 and rs2306283) gene loci with these variables. We studied 5411 participants in PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) (mean age 75.3 years), who had been randomized to pravastatin 40mg/day or placebo and were followed for a mean of 3.2 years. No relationships between genetic variation at the LXRA gene locus with statin induced LDL lowering response or other parameters were noted. Both the SLCO1B1 rs4149056 (valine for alanine at 174) and the rs2306283 (asparagine for aspartic acid at 130) SNPs affect the amino acid sequence of the SLCO1B1 gene product. No effect of the rs2306283 S...

Pravastatin Reduces Marfan Aortic Dilation

Journal of Vascular Surgery — Mon, 19 Dec 2011 23:06:57 +0100

Statins attenuate aortic root dilation in a mouse model of Marfan syndrome. Marfan syndrome derives from a relative lack of or abnormal fibrillin-1, resulting in vascular smooth muscle cells losing their ability to sense aortic wall strain. This leads to excessive transforming growth factor-β (TGF-β) release from the connective tissue matrix, resulting in excessive activation of smooth muscle cells and an inappropriate and haphazard remodeling process. The result is progressive dilation and weakening of the aorta and aortic root. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin), has pleiotropic anti-inflammatory effects. It reduces cardiac expression of TGF-β (Yu Y, et al, J Am Coll Cardiol 2004;44:904-13). Because TGF-β dysregulation can be attributed...

Influence of SLCO1B1 Polymorphisms on the Drug-Drug Interaction Between Darunavir/Ritonavir and Pravastatin.

The Journal of Clinical Pharmacology — Wed, 14 Dec 2011 05:00:00 +0100

Authors: Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS Abstract The authors investigated whether SLCO1B1 polymorphisms contribute to variability in pravastatin pharmacokinetics when pravastatin is administered alone versus with darunavir/ritonavir. HIV-negative healthy participants were prospectively enrolled on the basis of SLCO1B1 diplotype: group 1 (*1A/*1A, n = 9); group 2 (*1A/*1B, n = 10; or *1B/*1B, n = 2); and group 3 (*1A/*15, n = 1; *1B/*15, n = 5; or *1B/*17, n = 1). Participants received pravastatin (40 mg) daily on days 1 through 4, washout on days 5 through 11, darunavir/ritonavir (600/100 mg) twice daily on days 12 through 18, with pravastatin 40 mg added back on days 15 throug...

The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes

International Journal of Epidemiology — Fri, 09 Dec 2011 05:00:00 +0100

Conclusions In three independent populations, ALT in the normal range displayed an inverse relationship with total mortality, cardiovascular events and non-cardiovascular events in middle-to-older aged subjects without evidence of clinically significant liver damage, independent of traditional cardiovascular and other risk factors. These findings indicate that the relationship between ALT and clinical outcomes is more complex than generally appreciated. (Source: International Journal of Epidemiology)

BG Medicine, Inc. Announces Peer-Reviewed Publication on Galectin-3 and Development of Heart Failure After Acute Coronary Syndrome (ACS)

Medical News (via PRIMEZONE) — Wed, 30 Nov 2011 13:30:00 +0100

WALTHAM, Mass., Nov. 30, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today the availability of the peer-reviewed publication of the first clinical study on the role of galectin-3 in heart failure development. Results of the pilot study, which consisted of a sub-study of patients from the Pravastatin or Atorvastin Evaluation and Infection Therapy -- Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial, indicate that serum levels of galectin-3 are associated with increased risk of developing heart failure after suffering an acute coronary event, such as a heart attack. The study was conducted by the Boston-based TIMI Study Group at Brigham & Women's Hospital ...

MedWorm Sponsor Message: Find the best January Sales in the UK.

PRAVASTATIN SODIUMtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 30 Nov 2011 05:00:00 +0100

Updated Date: Nov 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pravastatin‐induced proangiogenic effects depend upon extracellular FGF‐2

Journal of Cellular and Molecular Medicine — Tue, 29 Nov 2011 10:28:13 +0100

AbstractThe HMG‐CoA reductase inhibitors (statins) have been shown to exert several protective effects on the vasculature that are unrelated to changes in the cholesterol profile, and to induce angiogenesis. The proangiogenic effect exerted by statins has been attributed to the activation of the PI3K/Akt pathway in endothelial cells; however, it is unclear how statins activate this pathway. Pravastatin‐mediated activation of Akt and MAPK occurs rapidly (within 10 min) and at low doses (0.01 μM). Here, we hypothesized that FGF‐2 contributes to the proangiogenic effect of statins. We found that pravastatin, a hydrophilic statin, induced phosphorylation of the FGF receptor (FGFR) in human umbilical vein endothelial cells. SU5402, an inhibitor of FGFR, abolished pravastatin‐induced PI...

Pravastatin-induced proangiogenic effects depend upon extracellular FGF-2.

J Cell Mol Med — Mon, 28 Nov 2011 05:00:00 +0100

Authors: Shiota M, Hikita Y, Kawamoto Y, Kusakabe H, Tanaka M, Izumi Y, Nakao T, Miura K, Funae Y, Iwao H Abstract The HMG-CoA reductase inhibitors (statins) have been shown to exert several protective effects on the vasculature that are unrelated to changes in the cholesterol profile, and to induce angiogenesis. The proangiogenic effect exerted by statins has been attributed to the activation of the PI3K/Akt pathway in endothelial cells; however, it is unclear how statins activate this pathway. Pravastatin-mediated activation of Akt and MAPK occurs rapidly (within 10 min) and at low doses (0.01 μM). Here, we hypothesized that FGF-2 contributes to the proangiogenic effect of statins. We found that pravastatin, a hydrophilic statin, induced phosphorylation of the FGF receptor (FGFR...

Inhibition of organic anion‐transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment

British Journal of Clinical Pharmacology — Thu, 24 Nov 2011 05:00:00 +0100

CONCLUSIONS: These findings suggest that quercetin inhibits the OATP1B1‐mediated transport of E3S and pravastatin in vitro, and also has a modest inhibitory influence on the pharmacokinetics of pravastatin in healthy Chinese‐Han male volunteers. The effects of quercetin on other OATP1B1 substrate drugs deserve further investigation. (Source: British Journal of Clinical Pharmacology)

Distinct effects of acute pretreatment with lipophilic and hydrophilic statins on myocardial stunning, arrhythmias and lethal injury in the rat heart subjected to ischemia/reperfusion.

Physiological Research — Tue, 22 Nov 2011 05:00:00 +0100

Authors: Carnická S, Adameová A, Nemčeková M, Matejíková J, Pancza D, Ravingerová T Abstract Although both lipophilic and more hydrophilic statins share the same pathway of the inhibition of HMG-CoA reductase, their pleiotropic cardioprotective effects associated with the ability to cross cellular membranes, including membranes of heart cells, may differ. To test this hypothesis, isolated rat hearts were Langendorff-perfused either with simvastatin (S, 10 micromol/l) or pravastatin (P, 30 micromol/l), 15 min prior to ischemia. Control untreated hearts (C) were perfused with perfusion medium only. Postischemic contractile dysfunction, reperfusion-induced ventricular arrhythmias and infarct size were investigated after exposure of the hearts to 30-min global ischemia and 2-h r...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability.

The Journal of Physiology — Mon, 21 Nov 2011 05:00:00 +0100

This study tested the hypothesis that treatment with statins depresses the fetal circulatory response to acute hypoxic stress via increasing NO bioavailability. Under anaesthesia, 12 fetal sheep at 118±1 days of gestation (term ca. 145d) were instrumented with vascular catheters and a femoral artery Transonic flow probe for chronic recording. Five days later, all animals were subjected to 30 min of acute hypoxia (fetal PaO2 reduced by ca. 50%) before and 24 h after fetal treatment with pravastatin (25 mg i.v.). In half of the fetuses, (n=6), responses to hypoxia post-pravastatin were evaluated during NO synthesis blockade. Fetal exposure to pravastatin did not affect fetal basal cardiovascular function. Fetal PaO2 was similarly reduced in all acute hypoxia experiments from ca. 21 to 10 mm...

PRAVASTATIN SODIUMtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 18 Nov 2011 05:00:00 +0100

Updated Date: Nov 18, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pravastatin inhibits C-reactive protein generation induced by fibrinogen, fibrin and FDP in isolated rat vascular smooth muscle cells

Inflammation Research — Wed, 16 Nov 2011 16:46:44 +0100

Conclusions Pravastatin at the concentrations used in the present experiment has ability to relieve vascular inflammation and to restrain atherosclerotic processes via inhibiting the CRP production induced by fibrinogen, fibrin and FDP in VSMCs, which helps explain the beneficial effects of pravastatin on atherosclerosis. Content Type Journal ArticleCategory Original Research PaperPages 1-8DOI 10.1007/s00011-011-0396-4Authors Fang Guo, Department of Pharmacology, Xi’an Jiaotong University School of Medicine, Postbox 58, 76 West Yanta Road, 710061 Xi’an, ChinaJun-Tian Liu, Department of Pharmacology, Xi’an Jiaotong University School of Medicine, Postbox 58, 76 West Yanta Road, 710061 Xi’an, ChinaChen-Jing Wang, Medical College of Northwest University for Nati...

Effect of Intensive Lipid-Lowering Therapy With Rosuvastatin on Progression of Carotid Intima-Media Thickness in Japanese Patients.

Circulation Journal — Wed, 16 Nov 2011 05:00:00 +0100

Conclusions: Rosuvastatin significantly slowed progression of carotid IMT at 12 months compared with pravastatin. PMID: 22094911 [PubMed - as supplied by publisher] (Source: Circulation Journal)

PRAVASTATIN SODIUMtablet [International Labs, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 15 Nov 2011 05:00:00 +0100

Updated Date: Nov 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pravachol [pravastatin] and Mevacor [lovastatin] have the best muscle-related safety profile of statins marketed in the US

Reactions — Thu, 10 Nov 2011 08:03:53 +0100

(Source: Reactions)

Potential role of statins on wound healing: review of the literature

International Wound Journal — Fri, 04 Nov 2011 04:00:00 +0100

Wound healing is a dynamic and complex biological process, which requires coordinated events including haemostasis, inflammation, proliferation, revascularisation and remodelling. Impaired wound healing is a common problem that occurs in both community and hospital settings. Various experimental and clinical studies have evaluated different modalities for the treatment of topical wounds, such as sugar, antibiotics, honey and phytotherapies; also statins have diverse pleiotropic effects that have been suggested to be useful to improve wound healing. Data derived from both animal and human studies showed that statins especially atorvastatin, simvastatin and pravastatin can accelerate the wound‐healing process. However, further high‐quality and evidence‐based studies are needed to addre...

Low‐dosage statins reduce choroidal damage in hypercholesterolemic rabbits

Acta Ophthalmologica — Tue, 01 Nov 2011 04:00:00 +0100

Conclusion: Treatment with a low dosage of fluvastatin sodium or pravastatin sodium reduced the lipid build‐up as well as the macrophages in the choroid and restored the vascular lumens of choroidal vessels independently of the cholesterol effect. The normal ultrastructural features of choroidal EC and VSMC in statin‐treated animals suggest that the endothelial function is preserved and the ischaemia reduced. (Source: Acta Ophthalmologica)

Lipid lowering drugs and gallstones: a therapeutic option?

Current Pharmaceutical Design — Tue, 01 Nov 2011 04:00:00 +0100

Authors: Lioudaki E, Ganotakis ES, Mikhailidis DP Abstract Cholelithiasis is a common disease worldwide. The majority of gallstones can occur when the bile is supersaturated with cholesterol. Dyslipidaemia, obesity, insulin resistance are associated with an increased risk for cholesterol gallstone formation as well as with vascular risk. Statins and ezetimibe are used to treat dyslipidaemia and appear to have some effect on bile composition and cholesterol gallstone formation. Statin (e.g. pravastatin, simvastatin, fluvastatin and lovastatin) monotherapy or combined with ursodeoxycholic acid (UDCA) have shown reductions in bile cholesterol saturation, preventing gallstone formation and even dissolving pre-existing stones. However, this effect was not consistently reported in all st...

Pitavastatin: Novel effects on lipid parameters.

Atherosclerosis. Supplements. — Tue, 01 Nov 2011 04:00:00 +0100

Authors: Chapman MJ Abstract Atherogenic dyslipidemia is characterised by high levels of triglycerides, low levels of high-density lipoprotein-cholesterol (HDL-C), and moderate to marked elevations in low-density lipoprotein-cholesterol (LDL-C) concentrations; such dyslipidemia is further characterised by high apolipoprotein B (apoB): apolipoprotein A1 (apoA1) ratios. Numerous clinical trials have demonstrated that statins are effective in lowering LDL-C and reducing cardiovascular (CV) risk in people with dyslipidemia. However, the most effective treatments should target all of the key atherogenic features, rather than LDL-C alone. Pitavastatin is a new member of the statin class whose distinct pharmacological features translate into a broad spectrum of action on both apoB-contain...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Do statins cut breast cancer recurrence?

NHS News Feed — Mon, 31 Oct 2011 10:31:00 +0100

Conclusion In this cohort study, use of a lipophilic statin (including simvastatin, the most commonly prescribed of the statins) was associated with a reduced risk of recurrent breast cancer in women with invasive breast cancer. The researchers also investigated the association between the exclusive use of simvastatin and the risk of recurrent breast cancer, and found that use of simvastatin reduced the risk of recurrent breast cancer compared to no statin treatment or treatment with a hydrophilic statin. Use of a hydrophilic (water-soluble) statin, including atorvastatin, pravastatin or rosuvastatin, was not found to be associated with reduced risk, though the strength of this result is limited by the small proportion of statin users (only 6%) who used this type of statin. The trial also...

Modifiers of Symptomatic Embolic Risk in Infective Endocarditis

Mayo Clinic Proceedings — Thu, 27 Oct 2011 04:00:00 +0100

CONCLUSION: The rate of symptomatic emboli associated with IE was reduced in patients who received continuous daily statin therapy before onset of IE. Despite fewer embolic events observed in patients who received antiplatelet agents, a significant association was not found after adjusting for propensity factors. A continued evaluation of these drugs and their potential impact on subsequent embolism among IE patients is warranted. (Source: Mayo Clinic Proceedings)

Dexamethasone/lenalidomide/pravastatin: Rhabdomyolysis in an elderly patient: case report

Reactions — Wed, 26 Oct 2011 13:05:18 +0100

(Source: Reactions)

A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein

International Journal of Cardiology — Mon, 24 Oct 2011 04:00:00 +0100

C-reactive protein (CRP) concentration has continuous associations with the risk of coronary heart disease, ischemic stroke, vascular mortality, and death from several cancers and lung disease that are each of broadly similar size . Beyond their ability to effectively lower low-density lipoprotein cholesterol, statins have consistently been shown to lower CRP levels by approximately 30% . Atorvastatin and rosuvastatin have been known to be high-intensity statins and expected to reduce CRP concentration more than other statins. In a meta-analysis, atorvastatin- (39.0%) and rosuvastatin-induced reductions (35.9%) in CRP levels are likely to be greater than pravastatin- (15.7%) and simvastatin-induced reductions (22.6%) . It remains unclear, however, which high-intensity statin, atorvastatin ...

Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells

The Journal of Thoracic and Cardiovascular Surgery — Thu, 20 Oct 2011 23:17:35 +0100

Objectives: Esophageal adenocarcinoma is an aggressive malignancy generally diagnosed after metastatic spread and currently lacks effective medical therapy. Expression of intracellular adhesion molecule-1 (ICAM-1) is an adverse prognostic indicator in various human tumor cells and contributes significantly to their metastatic potential. Statin therapy reduces circulating ICAM-1 levels in patients with coronary heart disease and is associated with reduction in progression from Barrett esophagus to esophageal adenocarcinoma. We hypothesize that statin therapy may attenuate growth and malignant potential via ICAM-1 expression and nuclear factor–kappa beta activation in human esophageal adenocarcinoma cells.Methods: Verified human esophageal adenocarcinoma cells (FLO-1) were treated with sim...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells

Respiratory Research — Fri, 14 Oct 2011 04:00:00 +0100

Conclusions: Lipophilic statins exert direct effects on distal human PASMCs and are likely to involve inhibition of Rho GTPase signalling. These findings compliment some of the recently documented effects in patients with pulmonary arterial hypertension. (Source: Respiratory Research)

Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses

BMC Medical Genetics - Latest articles — Thu, 06 Oct 2011 04:00:00 +0100

Conclusion With the GWAS in the PROSPER/PHASE study we confirm the previously found genetic associations with LDL-cholesterol levels. With this proof-of-principle study we show that the PROSPER/PHASE study can be used to investigate genetic associations in a similar way to population based studies. The next step of the PROSPER/PHASE study is to identify the genetic variation responsible for the variation in LDL-cholesterol lowering in response to statin treatment in collaboration with other large trials. (Source: BMC Medical Genetics - Latest articles)

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma

Clinical Endocrinology — Wed, 05 Oct 2011 14:50:23 +0100

SummaryMitotane [1‐(2‐chlorophenyl)‐1‐(4‐chlorophenyl)‐2,2‐dichloroethane, (o,p’‐DDD)] is the only drug approved for the treatment for adrenocortical carcinoma (ACC) and has also been used for various forms of glucocorticoid excess. Through still largely unknown mechanisms, mitotane inhibits adrenal steroid synthesis and adrenocortical cell proliferation. Mitotane increases hepatic metabolism of cortisol, and an increased replacement dose of glucocorticoids is standard of care during mitotane treatment. Recently, sunitinib, a multityrosine kinase inhibitor (TKI), has been found to be rapidly metabolized by CYP3A4 during mitotane treatment, indicating clinically relevant drug interactions with mitotane. We here summarize the current evidence concerning mitotane‐induced c...

PRAVASTATIN SODIUMtablet [International Labs, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 30 Sep 2011 05:00:00 +0100

Updated Date: Sep 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pravastatin's pharmacodynamics are not significantly affected by single nucleotide polymorphism rs4149056 in the gene SLC01B1

Reactions — Thu, 22 Sep 2011 07:55:36 +0100

(Source: Reactions)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

PRAVASTATIN SODIUMtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 22 Sep 2011 05:00:00 +0100

Updated Date: Sep 22, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The doubtful association between blood lipid changes and progression of atherosclerosis

International Journal of Cardiology — Wed, 21 Sep 2011 04:00:00 +0100

Recently Tenenbaum et al. reported that long-term changes in serum cholesterol did not correlate with the progression of coronary calcium measured by computerized tomography . Their finding shows that the benefit of various cholesterol-lowering treatments obtained in many angiographic trials must be caused by other and unknown factors. The authors argued that one of the reasons to the lack of exposure–response may be that calcific plaques are resistant to undergoing changes in size in response to systemic anti-atherosclerotic therapy. However, other studies using different techniques and other kinds of outcome have also shown lack of exposure–response. In a previous review of the angiographic cholesterol-lowering trials I identified sixteen trials in which the authors had calculated ex...

Low-Dose Pravastatin and Age-Related Differences in Risk Factors for Cardiovascular Disease in Hypercholesterolaemic Japanese: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study)

Drugs — Fri, 16 Sep 2011 02:05:54 +0100

(Source: Drugs)

The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin

Journal of Clinical Lipidology — Wed, 14 Sep 2011 04:00:00 +0100

Conclusion: In hyperlipidemic subjects with metabolic syndrome, atorvastatin is associated with a greater reduction in lipid markers of oxidation compared with pravastatin. Whether these effects are responsible for the outcome differences in trials comparing these agents needs further investigation. (Source: Journal of Clinical Lipidology)

No Evidence for Statin-induced Proteinuria in Healthy Volunteers as Assessed by Proteomic Analysis

International Journal of Biomedical Imaging — Tue, 13 Sep 2011 10:49:02 +0100

In clinical studies of statins (class of drugs lowering plasma cholesterol levels), transient low-molecular-weight proteinuria was observed. The causes of statin-induced proteinuria in the patient background of those studies (cardiovascular and kidney disease) are multifactorial and, therefore, a matter of debate. In light of this, it seemed interesting to investigate the effect of statins on the urinary protein concentration and proteome in healthy volunteers. Six healthy volunteers were randomly treated with rosuvastatin (40 mg/day) or pravastatin (80 mg/day) in a double-blinded cross-over study. Total urinary protein concentration and the concentration of albumin/retinol-binding protein were analysed, after which the urinary proteome was investigated. From the results desc...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pravastatin reduces marfan aortic dilation.

Circulation — Tue, 13 Sep 2011 04:00:00 +0100

Conclusions- Statins are similar to losartan in attenuating aortic root dilation in a mouse model of Marfan syndrome. They appear to act through reducing the excessive protein manufacture by vascular smooth muscle cells, which occurs in the Marfan aorta. As a drug that is relatively well-tolerated for long-term use, it may be useful clinically. PMID: 21911808 [PubMed - in process] (Source: Circulation)

Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: Role of vitamin D metabolites

Atherosclerosis — Fri, 02 Sep 2011 04:00:00 +0100

Conclusions: Pravastatin and atorvastatin have opposite effects on insulin sensitivity and vitamin D3 status. Pravastatin-induced increase in insulin sensitivity is mediated by elevation of 1,25-(OH)2-D3. In contrast, atorvastatin-induced decrease in insulin sensitivity is independent of lowering 25-OH-D3. (Source: Atherosclerosis)

Cardiac remodeling caused by transgenic overexpression of a corn Rac gene

AJP: Heart and Circulatory Physiology — Mon, 29 Aug 2011 23:00:00 +0100

In conclusion, this is the first study to show the conservation of Rho/Rac proteins between plant and animal kingdoms in vivo. Additionally, ZmRacD is a novel transgenic model that gradually develops a cardiac phenotype with aging. Furthermore, the shift from cardiac hypertrophy to dilated hearts via thyroxin treatment will provide us with an excellent system to study the temporal changes in cardiac signaling from adaptive to maladaptive hypertrophy and heart failure. (Source: AJP: Heart and Circulatory Physiology)

ERRATUM: Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels.

Clinical Pharmacology and Therapeutics — Sat, 27 Aug 2011 06:58:08 +0100

Authors: PMID: 21862969 [PubMed - in process] (Source: Clinical Pharmacology and Therapeutics)

The effects of a SNP in SLCO1B1 on the pharmacodynamics of pravastatin

British Journal of Clinical Pharmacology — Sat, 20 Aug 2011 15:49:38 +0100

Conclusion The rs4149056 SNP did not significantly affect the pharmacodynamics of pravastatin. (Source: British Journal of Clinical Pharmacology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Data-mining uncovers hyperglycemic drug-drug interaction between paroxetine and pravastatin

Drug Topics - Top News — Sun, 14 Aug 2011 00:17:28 +0100

Bioinformatics researchers at Stanford University have uncovered a never-before-reported drug-drug interaction between pravastatin and paroxetine. (Source: Drug Topics - Top News)

PRAVASTATIN SODIUMtablet [Cadila Healthcare Limited]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 12 Aug 2011 05:00:00 +0100

Updated Date: Aug 12, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Transport Characteristics of Tryptanthrin and its Inhibitory Effect on P-gp and MRP2 in Caco-2 Cells.

J Pharm Pharm Sci — Wed, 10 Aug 2011 13:45:06 +0100

Conclusions. Tryptanthrin was well absorbed across the Caco-2 monolayers, and its transepithelial transports were dominated by passive diffusion. Tryptanthrin was not a substrate, but a potential inhibitor of P-gp and MRP2. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page. PMID: 21824448 [PubMed - in process] (Source: J Pharm Pharm Sci)

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study.

Clinical Pharmacology and Therapeutics — Tue, 09 Aug 2011 23:00:00 +0100

Authors: Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, Sugiyama Y Abstract Clearance of atorvastatin occurs through hepatic uptake by organic anion transporting polypeptides (OATPs) and subsequent metabolism by cytochrome P450 (CYP) 3A4. To demonstrate the relative importance of OATPs and CYP3A4 in the hepatic elimination of atorvastatin in vivo, a clinical cassette microdose study was performed. A cocktail consisting of a microdose of atorvastatin along with probe substrates for OATPs (pravastatin) and CYP3A4 (midazolam) was orally administered to eight healthy volunteers. The pharmacokinetics of this cocktail was observed at baseline, after an oral dose of 600 mg rifampicin (an inhibitor of OATPs), and after an intravenous dose of 200 mg itracon...

PRAVASTATIN SODIUMtablet [Zydus Pharmaceuticals (USA) Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 08 Aug 2011 05:00:00 +0100

Updated Date: Aug 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pravastatin Versus Simvastatin for Prevention of Contrast-Induced Nephropathy

Journal of Cardiovascular Pharmacology and Therapeutics — Wed, 03 Aug 2011 23:00:00 +0100

In conclusion, patients on pravastatin had a significantly lower incidence of CIN compared to patients on simvastatin. (Source: Journal of Cardiovascular Pharmacology and Therapeutics)

Specific considerations on the prescription and therapeutic interchange of statins.

Farmacia Hospitalaria — Wed, 03 Aug 2011 23:00:00 +0100

CONCLUSION: The pharmacokinetics is important when choosing the best statin and could be a limitation in the use of interchange therapeutic programmes when other drugs are present. PMID: 21820929 [PubMed - as supplied by publisher] (Source: Farmacia Hospitalaria)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin.

International Journal of Hematology — Tue, 02 Aug 2011 23:00:00 +0100

Authors: Urata C, Yoshimura M, Itamura H, Hisatomi T, Kubota Y, Fukushima N, Sueoka E, Kimura S PMID: 21811773 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)

Data mining detects pravastatin/paroxetine interaction

Reactions — Mon, 01 Aug 2011 15:09:42 +0100

(Source: Reactions)

PRAVASTATIN SODIUMtablet [Teva Pharmaceuticals USA Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 29 Jul 2011 05:00:00 +0100

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients

Indian Journal of Pharmacology — Thu, 21 Jul 2011 23:00:00 +0100

Conclusions: The results of this study show that tacrolimus and statins do not interact in terms of efficacy, efficiency, and adverse effect likelihood. No significant clinical interaction or effect was observed, even with the use of atorvastatin or simvastatin, which are metabolized by CYP3A4 such as tacrolimus. (Source: Indian Journal of Pharmacology)

MedWorm Sponsor Message: Find the best January Sales in the UK.

PRAVASTATIN SODIUMtablet [Apotex Corp.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 20 Jul 2011 05:00:00 +0100

Updated Date: Jul 20, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease

International Journal of Cardiology — Mon, 18 Jul 2011 04:00:00 +0100

In a Cochrane Systematic Review by Navaneethan et al. of 11 randomized controlled trials (RCTs) (1 atorvastatin, 1 cerivastatin, 2 fluvastatin, 3 pravastatin, 4 simvastatin, and 1 rosuvastatin trials) including 548 patients with chronic kidney disease (CKD), there was no significant change in the average end of treatment value of creatinine clearance with statins in comparison to placebo. The Lipid Lowering and Onset of Renal Disease (LORD) trial , however, recently suggested that atorvastatin might reduce glomerular filtration rate (GFR) decline in patients with CKD. Furthermore, a subanalysis (3107 patients) of a large RCT, Treating to New Targets (TNT) study , also showed that atorvastatin improved GFR which was significantly greater with 80mg than with 10mg in patients with coronary he...

HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7

Atherosclerosis — Thu, 14 Jul 2011 23:00:00 +0100

Abstract: We recently reported that the endogenous ATP-binding cassette transporter (ABC) A7 strongly associates with phagocytosis, being regulated by sterol regulatory element binding protein 2. We therefore examined the effect of statins on phagocytosis in vitro and in vivo through the SREBP–ABCA7. Phagocytosis was found to be enhanced by pravastatin, rosuvastatin and simvastatin and cyclodextrin in J774 macrophages, as cellular cholesterol was reduced and expressions of the cholesterol-related genes were modulated, including an increase of ABCA7 mRNA and decrease of ABCA1 mRNA. Conversely, knock-down of ABCA7 expression by siRNA ablated enhancement of phagocytosis by statins. In vivo, pravastatin enhanced phagocytosis in wild-type mice, but not in ABCA7-knockout mice. We thus conclude...

Circulating Interleukin-10 and Risk of Cardiovascular Events: A Prospective Study in the Elderly at Risk.

Arteriosclerosis, Thrombosis and Vascular Biology — Wed, 13 Jul 2011 23:00:00 +0100

CONCLUSIONS: Baseline circulating levels of the antiinflammatory IL-10 are positively associated with risk of CVD among the elderly without prior CVD events, although the association is less evident in those with a history of CVD. Additional epidemiological and mechanistic studies investigating the role of IL-10 in CVD are warranted. PMID: 21757655 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)

Data Mining Approach Shows Promise in Detecting Unexpected Drug Interactions

ICMCC: The International Council on Medical and Care Compunetics — Wed, 13 Jul 2011 12:58:43 +0100

Source: Hampton T. JAMA, 306(2) Content: Up to 1 million patients in the United States may be taking 2 medications that can lead to unexpected increases in blood glucose levels when used simultaneously. Data mining techniques have revealed that the combination of the antidepressant paroxetine and the cholesterol-lowering medication pravastatin may cause this adverse effect [...] (Source: ICMCC: The International Council on Medical and Care Compunetics)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Paroxetine, pravastatin, and impaired blood glucose control: an elegant use of adverse event reports

NeLM - News — Tue, 12 Jul 2011 23:00:00 +0100

Source: Clinical Pharmacology and Therapeutics, JAMA Area: News JAMA today includes a news item describing how a team identified and confirmed an unexpected drug interaction using data mining techniques on US FDA adverse event reports. Data mining is a technique for extracting hidden information from large databases: scientifically, it is potentially valuable for creating novel hypotheses. The authors of this study note that discovering unpredictable drug interactions is a challenge, however spontaneous adverse event reporting systems provide an opportunity to study interaction effects. They reasoned that it might be possible to identify drug interactions through analysis of adverse events rather than direct reporting, and developed an algorithm to study diabetes-related effect...

Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment

Experimental Dermatology — Mon, 11 Jul 2011 23:00:00 +0100

In this study, we explored an inhibitory effect of statins on CCL20/CCR6 interaction. We demonstrated that IL‐1β, TNF‐α, and IL‐17A significantly increased CCL20 production from HaCaT cells. However, these increments were markedly inhibited by fluvastatin and simvastatin, but not by pravastatin. In the chemotaxis migration assay, pretreatment with fluvastatin and simvastatin inhibited the migration of human CD4+ T cells toward CCL20. However, the level of CCR6 surface expression in memory CD4+ T cells was not affected. Our results suggest that not all, but specific types of statins may be of benefit in alleviating psoriasis partially via interrupting CCL20/CCR6 chemotactic interaction, the mechanism which may eventually lessen the infiltration of Th17 cells. (Source: Experimental D...

The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer’s disease in rats

Journal of Neural Transmission — Sun, 10 Jul 2011 05:51:45 +0100

Abstract Astrocytes play a fundamental role in glutamate metabolism by regulating the extracellular levels of glutamate and intracellular levels of glutamine. They also participate in antioxidant defenses, due to the synthesis of glutathione, coupled to glutamate metabolism. Although the cause of Alzheimer’s disease (AD) remains elusive, some changes in neurochemical parameters, such as glutamate uptake, glutamine synthetase activity and glutathione have been investigated in this disease. A possible neuroprotective effect of two statins, simvastatin and pravastatin (administered p.o.), was evaluated using a model of dementia, based on the intracerebroventricular (ICV) administration of streptozotocin (STZ), and astrocyte parameters were determined. We confirmed a cogniti...

Statins Promote the Growth of Experimentally Induced Cerebral Aneurysms in Estrogen-Deficient Rats.

Stroke — Wed, 06 Jul 2011 23:00:00 +0100

CONCLUSIONS: Our results provide the first evidence that cerebral aneurysm growth is partly associated with apoptosis and issue a warning that statins exert bidirectional effects on cerebral aneurysms. Additional intensive research is necessary to understand better their mechanisms and to identify patients in whom the administration of statins may elicit deleterious effects. PMID: 21737796 [PubMed - as supplied by publisher] (Source: Stroke)

Long-term Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With MicroalbuminuriaLong-term Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria

Medscape Today Headlines — Thu, 30 Jun 2011 11:04:26 +0100

An ACE in-the-hole may ward off adverse outcomes in patients with elevated urinary albumin excretion. American Heart Journal (Source: Medscape Today Headlines)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability.

Paediatric Drugs — Thu, 30 Jun 2011 10:30:07 +0100

Conclusions: In this large cohort of FH children, the efficacy and tolerability of pravastatin therapy in real-life conditions was demonstrated to be similar to that in randomized controlled studies. PMID: 21692550 [PubMed - in process] (Source: Paediatric Drugs)

Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1–induced preeclampsia

American Journal of Obstetrics and Gynecology — Thu, 30 Jun 2011 04:00:00 +0100

Conclusion: Pravastatin prevents vascular dysfunction in part by up-regulation of eNOS in the vasculature. Our data support a role for statins in preeclampsia prevention. (Source: American Journal of Obstetrics and Gynecology)

Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial

Cardiovascular Diabetology — Wed, 29 Jun 2011 23:00:00 +0100

Background: Although the ADA/EASD/IDF International Expert Committee recommends using hemoglobin A1c (HbA1c) to define diabetes, the relation between HbA1c and cardiovascular disease (CVD) has not been thoroughly investigated. We analyzed this relation using clinical data on Japanese individuals with hypercholesterolemia. Methods: In the large-scale MEGA Study 7832 patients aged 40 to 70 years old with mild- to- moderate hypercholesterolemia without CVD were randomized to diet alone or diet plus pravastatin and followed for >5 years. In the present subanalysis of that study a total of 4002 patients with baseline and follow-up HbA1c data were stratified according to having an average HbA1c during the first year of follow-up (Source: Cardiovascular Diabetology)

Statins and diabetes risk

NHS News Feed — Wed, 22 Jun 2011 18:15:00 +0100

Conclusion This systematic review and meta-analysis suggests that intensive-dose statin therapy is associated with an increased risk of diabetes compared to moderate-dose statins. However, intensive use also reduces the risk of cardiovascular events, such as heart attacks or strokes. The study used appropriate methods to investigate this question and, importantly, gives us an idea of the trade-off between benefits and harms of intensive-dose statin therapy. There are some points to note: The trials included varied in their methods of diagnosing diabetes, which could affect the reliability of the pooled results. However, the researchers performed statistical tests and applied different types of analyses to the data. This suggests that, despite these differences in method, the trials all...

Networking prescriptions

ICMCC: The International Council on Medical and Care Compunetics — Tue, 21 Jun 2011 14:10:59 +0100

Source: Jyoti M., NextBio's Blog Content: “Going paperless with patient records could benefit more than just the trees, according to a new study published in Clinical Pharmacology and Therapeutics. Based entirely on electronic medical records, the research finds an intriguing association between higher blood glucose levels and combining prescriptions for two drugs, pravastatin and paroxetine. Pravastatin [...] (Source: ICMCC: The International Council on Medical and Care Compunetics)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

PRAVACHOL (Pravastatin Sodium) Tablet [E.R. Squibb Sons, L.L.C.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 09 Jun 2011 05:00:00 +0100

Updated Date: Jun 9, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

PRAVASTATIN SODIUMtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 08 Jun 2011 05:00:00 +0100

Updated Date: Jun 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Pravastatin for thioacetamide‐induced hepatic failure and encephalopathy

European Journal of Clinical Investigation — Mon, 06 Jun 2011 23:00:00 +0100

Conclusions Pravastatin ameliorates hepatic encephalopathy and liver biochemistry and improves survival in rats with acute liver failure, but not in those with cirrhosis. (Source: European Journal of Clinical Investigation)

Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease

Heart and Vessels — Sat, 04 Jun 2011 05:52:59 +0100

This study included 76 patients with CAD and 15 subjects without CAD (non-CAD). CAD patients were randomized to 6 months of intensive LLT with atorvastatin or moderate LLT with pravastatin. Plasma leptin, angiopoetin-2 (Ang-2), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) levels were measured prior to statin therapy (baseline) and after 6 months. Baseline levels of leptin, Ang-2, HGF and VEGF were higher in the CAD group than in the non-CAD group (all P < 0.05). Treatment with intensive LLT decreased leptin, Ang-2, HGF and VEGF levels, whereas moderate LLT did not change these levels. This study suggests that LLT with atorvastatin decreases leptin levels and angiogenic factors in patients with CAD, possibly contributing to the be...

PRAVASTATIN SODIUMtablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 03 Jun 2011 05:00:00 +0100

Updated Date: Jun 3, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome

European Heart Journal — Tue, 31 May 2011 23:00:00 +0100

Conclusion Neopterin levels are an independent predictor of HF hospitalization, and improve risk prediction over and above conventional biomarkers. http://www.clinicaltrials.gov/ registration number NCT00382460. (Source: European Heart Journal)

PRAVASTATIN SODIUMtablet [American Health Packaging]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 27 May 2011 05:00:00 +0100

Updated Date: May 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Cardiac Remodeling Caused by Transgenic Over-expression of a Corn Rac Gene.

American Journal of Physiology. Heart and Circulatory Physiology — Thu, 26 May 2011 23:00:00 +0100

In conclusion, this is the first study to show the conservation of Rho/Rac proteins between plant and animal kingdoms in-vivo. Additionally, ZmRacD is a novel transgenic model that gradually develops cardiac phenotype with aging. Furthermore, the shift from cardiac hypertrophy to dilated hearts via T4 treatment will provide us with an excellent system to study the temporal changes in cardiac signaling from adaptive to maladaptive hypertrophy and heart failure. PMID: 21622832 [PubMed - as supplied by publisher] (Source: American Journal of Physiology. Heart and Circulatory Physiology)

Cardioprotective Effects of Pravastatin Against Lethal Ventricular Arrhythmias Induced by Reperfusion in the Rat Heart.

Circulation Journal — Tue, 24 May 2011 23:00:00 +0100

Conclusions: Pravastatin attenuated reperfusion-induced lethal ventricular arrhythmias. Inhibition of [Ca(2+)](i) overload and preserving Δψ(m) may be the mechanisms of the observed antiarrhythmic effects of pravastatin. PMID: 21613743 [PubMed - as supplied by publisher] (Source: Circulation Journal)

Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels.

Clinical Pharmacology and Therapeutics — Tue, 24 May 2011 23:00:00 +0100

Authors: Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, Castro V, Yue P, Tsau PS, Kohane I, Roden DM, Altman RB The lipid-lowering agent pravastatin and the antidepressant paroxetine are among the most widely prescribed drugs in the world. Unexpected interactions between them could have important public health implications. We mined the US Food and Drug Administration's (FDA's) Adverse Event Reporting System (AERS) for side-effect profiles involving glucose homeostasis and found a surprisingly strong signal for comedication with pravastatin and paroxetine. We retrospectively evaluated changes in blood glucose in 104 patients with diabetes and 135 without diabetes who had received comedication with these two drugs, using data in electronic medical record (EMR) systems of thr...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.

Xenobiotica — Tue, 24 May 2011 23:00:00 +0100

This study has characterized insect cell- and mammalian cell-derived ABC-transporter-expressing membrane vesicle test systems and validated methodologies for evaluation of candidate drugs as substrates or inhibitors of BCRP or MRP2. Concentration-dependent uptake of BCRP ([(3)H]oestrone 3-sulfate, [(3)H]methotrexate, [(3)H]rosuvastatin) and MRP2 ([(3)H]oestradiol 17β-glucuronide, [(3)H]pravastatin, carboxydichlorofluorescein) substrates, and inhibitory potencies (IC(50)) of BCRP (sulfasalazine, novobiocin, fumitremorgin C) and MRP2 (benzbromarone, MK-571, terfenadine) inhibitors were determined. The apparent K(m) for probes [(3)H]oestrone 3-sulfate and [(3)H]oestradiol 17β-glucuronide was determined in insect cell vesicles to be 7.4 ± 1.7 and 105 ± 8.3 µM, respectively. All ...

Response to letter by Mascitelli et al.

Pain — Tue, 24 May 2011 23:00:00 +0100

We thank Drs Mascitelli, Grant, and Goldstein for their interest in our work which suggests that statins may be beneficial in alleviating neuropathic pain . Dr Mascitelli and colleagues pointed out that statins might have nerve-related toxic effects and proposed vitamin D supplementation as an alternative. We are aware that there are some case reports and case–control studies in the literature indicating the potential risk of peripheral neuropathy with statin therapy. However, these case reports have been refuted by more recent large clinical trials. In the Heart Protection Study (HPS), one of the largest (N=20,536), randomized, placebo-controlled clinical trial of simvastatin (40mg/d), peripheral neuropathy was recorded in 11 patients who received simvastatin and in 8 patients who recei...

PRAVASTATIN SODIUMtablet [TEVA Pharmaceuticals USA Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 23 May 2011 05:00:00 +0100

Updated Date: May 23, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia

Journal of Human Hypertension — Wed, 18 May 2011 23:00:00 +0100

Authors: T Kushiro, K Mizuno, N Nakaya, Y Ohashi, T Teramoto, S Yokoyama, S Kakinoki & H Nakamura (Source: Journal of Human Hypertension)

PRAVASTATIN SODIUMtablet [TEVA Pharmaceuticals USA Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 18 May 2011 05:00:00 +0100

Updated Date: May 18, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Statins Before PCI Protect Microvasculature (CME/CE)

MedPage Today Cardiovascular — Tue, 17 May 2011 16:00:00 +0100

(MedPage Today) -- Pretreating PCI patients with pravastatin can help reduce microvascular dysfunction induced by PCI regardless of side branch occlusion, Japanese researchers found. (Source: MedPage Today Cardiovascular)

PRAVASTATIN SODIUMtablet [Zydus Pharmaceuticals (USA) Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 16 May 2011 05:00:00 +0100

Updated Date: May 16, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

The Impact of Pravastatin Pre-Treatment on Periprocedural Microcirculatory Damage in Patients Undergoing Percutaneous Coronary Intervention

Journal of the American College of Cardiology: Cardiovascular Interventions — Sun, 15 May 2011 23:00:00 +0100

Conclusions Post-PCI measurement of the IMR confirmed that pre-treatment with pravastatin was associated with reduced microvascular dysfunction induced by PCI regardless of side branch occlusions. These data suggest that pre-treatment with statin is desired in patients undergoing elective PCI. (The Impact of Pravastatin Pretreatment on Periprocedural Microcirculatory Damage After Percutaneous Coronary Intervention; UMIN000002885) (Source: Journal of the American College of Cardiology: Cardiovascular Interventions)

Effects of single-dose morning and evening administration of pravastatin on antioxidant markers in cholesterol-fed rabbits

International Journal of Nanomedicine — Sat, 14 May 2011 06:12:36 +0100

Kamal S (Source: International Journal of Nanomedicine)

PRAVASTATIN SODIUMtablet [Cadila Healthcare Limited]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 13 May 2011 05:00:00 +0100

Updated Date: May 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22)

American Heart Journal — Wed, 11 May 2011 23:00:00 +0100

Conclusions: Higher adiponectin concentrations early after ACS are independently associated with a higher risk of recurrent cardiovascular events. This finding is directionally opposite to that observed in patients at risk for atherosclerosis and reveals the need for investigation to elucidate differences in the pathobiology of adiponectin in stable versus unstable coronary artery disease. (Source: American Heart Journal)

Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT)

American Heart Journal — Wed, 11 May 2011 23:00:00 +0100

Conclusions: Elevated UAE is associated with increased cardiovascular mortality and morbidity after 9.5 years of follow-up, with a doubling of the risk if the UAE is >50 mg per 24 hours. In this group, the benefits of 4-year treatment with fosinopril were sustained during posttrial follow-up for cardiovascular mortality and morbidity. We propose that UAE be used to estimate risk in the general population and that large clinical trials be designed to confirm the hypothesis that angiotensin-converting enzyme–inhibitor treatment may be beneficial in patients with mildly elevated UAE despite the absence of other comorbidities. (Source: American Heart Journal)

Efficacy of Ezetimibe/Statins and Statin Monotherapy and Factors Associated with Treatment Response: Pooled Analysis of >21,000 Subjects from 27 Trials

Journal of Clinical Lipidology — Sat, 30 Apr 2011 23:00:00 +0100

Synopsis: Use of a large pooled database from multiple clinical trials provides additional power to assess the efficacy of lipid-altering therapy. Purpose: To evaluate the lipid-altering efficacy of ezetimibe co-administered with statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and statin monotherapy. Identify factors related to treatment response. (Source: Journal of Clinical Lipidology)

The incidence and risk factors for new onset atrial fibrillation in the PROSPER study

Europace — Thu, 21 Apr 2011 23:00:00 +0100

Conclusion Pravastatin does not reduce the incidence of AF in older people at risk of vascular disease, at least in the short–medium term. Risk factors for AF include older age, prolongation of PR or QTc intervals, left ventricular hypertrophy, and ST-T abnormalities on the ECG. (Source: Europace)

Effect of Statins on Cholesterol Crystallization and Atherosclerotic Plaque Stabilization

The American Journal of Cardiology — Wed, 20 Apr 2011 23:00:00 +0100

Pleiotropic effects of statins have not been fully elucidated. Recently we demonstrated that cholesterol expands when crystallizing and may trigger plaque rupture. The present study evaluated the potential direct effects of statins in altering cholesterol crystallization as a possible mechanism for plaque stabilization independent of cholesterol lowering. Cholesterol powder was dissolved in oil with and without pravastatin, simvastatin, or atorvastatin (10 to 90 mg) and then allowed to crystallize to measure peak volume expansion (ΔVE) in graduated cylinders. Effect of ΔVE on fibrous membrane damage was also evaluated. Human coronary, carotid, and peripheral arterial plaques (65 plaques from 55 patients) were incubated with statin or saline solution using matched plaque segments to evalu...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis

Journal of Gastroenterology and Hepatology — Tue, 19 Apr 2011 17:14:18 +0100

Conclusions: Pravastatin rendered a positive reduction in BDO‐induced increases in plasma bile acid concentrations and cholesterol liver content, mainly through the transcriptionally‐mediated down‐regulation of genes involved in the synthesis of these compounds in the liver. (Source: Journal of Gastroenterology and Hepatology)

Treatment of indeterminate cell histiocytosis with pravastatin

Journal of the American Academy of Dermatology — Fri, 15 Apr 2011 17:11:06 +0100

To the Editor: A 41-year-old woman with a history of systemic lupus erythematosus presented to our clinic with a several-month history of a diffuse papular eruption, arising primarily in her axillae, groin, submammary regions, and upper cutaneous lip. The lesions were yellow brown and minimally pruritic (, A). Initial lab work was significant only for modestly elevated total cholesterol and triglycerides. (Source: Journal of the American Academy of Dermatology)

Statin Myopathy: A Lipid Clinic Experience on the Tolerability of Statin Rechallenge

Cardiovascular Therapeutics — Thu, 31 Mar 2011 23:00:00 +0100

Conclusions: Statin rechallenge is a real treatment option in patients with statin myopathy. Detailed history and examination is required to exclude muscle diseases unrelated to statin usage. In patients developing statin myopathy on simvastatin, we did not find any statistical difference between subsequent tolerability rates to rosuvastatin, pravastatin, and fluvastatin. (Source: Cardiovascular Therapeutics)

Statins potently reduce the cytokine‐mediated IL‐6 release in SMC/MNC cocultures

Journal of Cellular and Molecular Medicine — Thu, 31 Mar 2011 23:00:00 +0100

AbstractInflammatory pathways are involved in the development of atherosclerosis. Interaction of vessel wall cells and invading monocytes by cytokines may trigger local inflammatory processes. 3‐Hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) are standard medications used in cardiovascular diseases. They are thought to have anti‐inflammatory capacities, in addition to their lipid‐lowering effects. We investigated the anti‐inflammatory effect of statins in the cytokine‐mediated‐interaction‐model of human vascular smooth muscle cells (SMC) and human mononuclear cells (MNC). In this atherosclerosis‐related inflammatory model LPS (lipopolysaccharide, endotoxin), as well as high mobility group box 1 stimulation resulted in synergistic (i.e. over‐additive...

PRAVASTATIN SODIUM (Pravastatin Sodium) Tablet PRAVASTATIN SODIUM ( Pravastatin Sodium ) Tablet PRAVASTATIN SODIUM (Pravastatin Sodium ) Tablet [LUPIN PHARMACEUTICALS INC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 31 Mar 2011 05:00:00 +0100

Updated Date: Mar 31, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Increased amygdalar and hippocampal volumes in elderly obese individuals with or at risk of cardiovascular disease.

The American Journal of Clinical Nutrition — Tue, 29 Mar 2011 23:00:00 +0100

CONCLUSIONS: This study showed that the amygdala and hippocampus are enlarged in obesity. In consideration of the function of these structures, this finding may indicate that hedonic memories could be of major importance in the regulation of feeding. Because of the cross-sectional design, cause and effect could not be discriminated in this study. PMID: 21450935 [PubMed - as supplied by publisher] (Source: The American Journal of Clinical Nutrition)

Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells

Naunyn-Schmiedeberg's Archives of Pharmacology — Tue, 29 Mar 2011 17:31:20 +0100

Abstract Statins exert anti-inflammatory effects and downregulate matrix metalloproteinases (MMPs) expression, thus contributing to restore cardiovascular homeostasis in cardiovascular diseases. We aimed at comparing the effects of different statins (simvastatin, atorvastatin, and pravastatin) on MMP-2, MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1, TIMP-2, and MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios released by human umbilical vein endothelial cells (HUVEC) stimulated by phorbol myristate acetate (PMA). HUVECs were incubated with statins (0.1–10 μM) for 12 h before stimulation with PMA 100 nM. Monolayers were used to perform cell viability assays and the supernatants were collected to determine MMPs and TIMPs levels by gelatin zymography and/or en...

The effect of dyslipidemic drugs on mortality: a meta-analysis

NeLM - Disease Focused Reviews — Sun, 27 Mar 2011 23:00:00 +0100

Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This review evaluated the effect of lipid-lowering drugs on coronary artery disease and cardiovascular disease mortalities, and all-cause mortality. The authors concluded that reductions of 15 to 25% in the relative odds of developing these outcomes can be achieved. This was largely a well-conducted review, but the absence of trial quality assessment represents a threat to the reliability of findings. [The included drugs were cholestyramine, clofibrate, fluvastatin, gemfibrozil, lovastatin, pravastatin and simvastatin.] CRD Commentary: This review addressed a clear research question. This was supported by inclusion criteria, which were detailed for study design and outcomes, and broad for the intervention of interest. ...

Statins as modulators of colon cancer cells induced cytokine secretion by human PBMC.

Vascular Pharmacology — Sat, 26 Mar 2011 00:00:00 +0100

Authors: Bergman M, Salman H, Djaldetti M, Bessler H The study was designed to examine whether the hydrophilic statin - pravastatin and the hydrophobic statin - simvastatin affect colon cancer cell-induced cytokine secretion by peripheral blood mononuclear cells (PBMC). Statins were added to human colon cancer cells (HT-29 and RKO), or to PBMC incubated separately or jointly. The secretion of the pro-inflammatory cytokines IL-1β and IFNγ and that of the anti-inflammatory cytokines IL-1ra and IL-10 induced by cancer cells was decreased by simvastatin but not by pravastatin, whereas that of IL-6 was not affected by both drugs. Conditioned media from colon cancer cells incubated with either simvastatin or pravastatin induced stimulation of cytokine production by PBMC similar to that cau...

Aspirin/cephalosporins/pravastatin: Toxic epidermal necrolysis: case report

Reactions — Tue, 22 Mar 2011 17:01:08 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Statins for the prevention and treatment of infections: a systematic review and meta-analysis

NeLM - Disease Focused Reviews — Mon, 21 Mar 2011 00:00:00 +0100

Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This review concluded that statin use may be associated with benefits in treating and preventing infections, but given the heterogeneity between studies and evidence of publication bias, randomised controlled trials are needed to confirm this benefit of statin use. These conclusions are likely to be reliable. [Statins used were atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin and simvastatin.] CRD Commentary: The review question and the inclusion criteria were clear. The authors searched several relevant databases, including one which listed conference abstracts. This, together with the lack of language restrictions, reduced the chances of relevant studies being omitted or biases being introduced. Howev...

Pravastatin therapy fails to suppress post-PCI inflammatory response measured by serum neopterin and CRP levels.

Anadolu Kardiyol Der... — Mon, 21 Mar 2011 00:00:00 +0100

CONCLUSION: Percutaneous coronary intervention induces a pronounced inflammatory response. The pre-procedural administration of 2 different doses of pravastatin seems not enough to suppress this inflammation at the short-term follow-up. Further trials are needed to clarify this issue. PMID: 21421511 [PubMed - as supplied by publisher] (Source: Anadolu Kardiyol Der...)

Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol

International Journal of Cardiology — Mon, 21 Mar 2011 00:00:00 +0100

It is well established that the risks of major cardiovascular events are reduced by a broad range of statins, including atorvastatin and pravastatin, and the size of the low-density lipoprotein (LDL) cholesterol reduction is an important determinant of the size of these treatment effects . It remains uncertain, however, whether mechanisms independent of LDL cholesterol also affect the size of the treatment benefit, and there have been few formal attempts to investigate any such drug-specific effects. Our preliminary analysis suggested modestly greater protection against major coronary heart disease (CHD) events independent of LDL cholesterol lowering with atorvastatin than pravastatin. Updating our previous analysis , we conducted an analysis to determine the relative contribution of more ...

Development of a model for prediction of coronary atherosclerotic regression: evaluation of high-density lipoprotein cholesterol level and peripheral blood monocyte count

Heart and Vessels — Thu, 17 Mar 2011 18:15:57 +0100

Abstract Monocytes and high-density lipoprotein cholesterol (HDL-C) play important roles in the process of coronary atherosclerosis. We hypothesized that a reasonable predictive model of coronary plaque regression might be constructed using the change in the peripheral monocyte count and the serum HDL-C level. The plaque volume, as assessed by volumetric intravascular ultrasound, was measured at the baseline and after 6 months of pravastatin therapy in 114 patients with coronary artery disease. After 6 months of pravastatin therapy, a significant decrease of the plaque volume by 9.9% (p < 0.0001, vs. baseline) was observed; furthermore, a corresponding increase of the serum HDL-C level and decrease of the peripheral blood monocyte count were also seen (12....

Is telomerase a potential target for vascular rejuvenation?

Atherosclerosis — Thu, 17 Mar 2011 00:00:00 +0100

As life expectancy will further increase over the next decades, age-related diseases will represent a major challenge for every health system, shifting its needs from treatment to prevention. On a cellular level, the deteriorating proliferative and differentiation potential that goes along with advancing age is paralleled by the functional decline of organs, their unresponsiveness to stress and an increase in disease. Ageing is complicated by the diminishing self-renewal capacity of our bodies, which is normally maintained by reservoirs of somatic tissue stem cells. Most signalling pathways involved in ageing are related to genotoxic stress, where important causes are impaired DNA repair, telomere damage and radical oxygen species (ROS). Telomeres are DNA repeats at the ends of chromosomes...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients

NeLM - Disease Focused Reviews — Tue, 15 Mar 2011 00:00:00 +0100

Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This review concluded that statin treatment used for the primary prevention of cardiovascular disease was effective in reducing cardiovascular death and other major cardiovascular events. The conduct and reporting of the review were good and the conclusions are likely to be reliable. [Included studies assessed atorvastatin, fluvastatin, pravastatin and lovastatin.] CRD Commentary: The inclusion criteria for this review were clearly stated. The search was extensive and no language restrictions were applied, thus the possibility of missed studies and the introduction of publication and language biases was reduced. The authors stated that tests showed no evidence of publication bias. The methods used for study selection a...

Treatment with pravastatin attenuates progression of chronic pancreatitis in rat

Laboratory Investigation AOP — Mon, 07 Mar 2011 00:00:00 +0100

Authors: Limin Wei, Mitsuyoshi Yamamoto, Masaru Harada & Makoto Otsuki (Source: Laboratory Investigation AOP)

Pravastatin does not protect elderly against VTE

MedWire News - Lipidology — Fri, 04 Mar 2011 11:07:01 +0100

Pravastatin does not prevent venous thromboembolism in elderly people at risk for cardiovascular disease, study findings indicate. (Source: MedWire News - Lipidology)

Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

BMC Geriatrics — Tue, 22 Feb 2011 00:00:00 +0100

Conclusions: Pravastatin does not prevent VTE in elderly people at risk of vascular disease. Blood markers of haemostasis and inflammation are not strongly predictive of VTE in older age however BMI, country and lower systolic blood pressure are independently associated with VTE risk. (Source: BMC Geriatrics)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Treatment With Pravastatin Attenuates Oxidative Stress and Protects Osteoblast Cell Viability From Indoxyl Sulfate

Therapeutic Apheresis and Dialysis — Sun, 20 Feb 2011 00:00:00 +0100

AbstractChronic kidney disease has a high level of oxidative stress, a phenomenon that is induced, at least in part, by the accumulation of uremic toxins. Several reports have revealed that indoxyl sulfate, one of the uremic toxins, accelerates oxidative stress in chronic kidney disease. On the other hand, it is also well known that statins have pleiotropic effects; however, it still remains unclear whether statins suppress osteoblastic cell dysfunction or cytotoxicity induced by uremic toxins. To elucidate whether statins ameliorate osteoblast dysfunction induced by uremic toxins, we conducted an in vitro study using primary cultured osteoblastic cells from mouse calvariae. Indoxyl sulfate induced reactive oxygen species production and reduced cell viability in osteoblastic cells in a dos...

PRAVASTATIN SODIUMtablet [Med Health Pharma LLC.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 18 Feb 2011 05:00:00 +0100

Updated Date: Feb 18, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

PRAVASTATIN SODIUMtablet [Med Health Pharma LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 18 Feb 2011 05:00:00 +0100

Updated Date: Feb 18, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants

Contemporary Clinical Trials — Mon, 14 Feb 2011 00:00:00 +0100

Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney condition and is associated with important renal and cardiovascular manifestations in childhood. Renal cystic disease can be documented in some cases as early as in utero. Early intervention is critical if the long-term complications of this condition, including end-stage renal disease, are to be ameliorated. Here we describe our ongoing randomized double-blind placebo-controlled phase III clinical trial to assess the effect of pravastatin treatment on renal and cardiovascular disease progression in 107 children and young adults age 8–22years with ADPKD who are receiving the angiotensin converting enzyme inhibitor lisinopril. Baseline demographic and laboratory data are provided. Results of t...

pravastatin, Pravachol

MedicineNet Cholesterol General — Fri, 11 Feb 2011 07:00:00 +0100

Title: pravastatin, PravacholCategory: MedicationsCreated: 12/31/1997Last Editorial Review: 2/11/2011 (Source: MedicineNet Cholesterol General)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Genetic Marker of Statin-induced Rhabdomyolysis.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan — Tue, 01 Feb 2011 00:00:00 +0100

Authors: Chiba K, Morimoto K This review summarizes genetic factors predisposed to statin-induced rhabdomyolysis. The first genetic risk factor of statin myopathy uncovered by genome-wide analysis of single nucleotide polymorphisms was the common variant of SLCO1B1 gene. Analysis of 30000 genetic markers in 85 patients with myopathy induced by high-dose simvastatin showed a strong association with 521T>C polymorphism of SLCO1B1. Another study also showed that this variant of SLCO1B1 has a significant association with myopathy in patients taking pravastatin or atorvastatin although the number of patients analyzed was limited. In addition to SLCO1B1, recent studies suggested that variants of genes encoding transporters (ABCG2 and ABCB1) and metabolic enzymes (CYP2C8 and UGT1A3) involv...

Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes

Annals of Clinical Biochemistry — Thu, 27 Jan 2011 00:00:00 +0100

Statins are agents widely used to lower LDL-cholesterol (LDL-C) in primary and secondary prevention of coronary heart disease. The five statins available in the UK (simvastatin, pravastatin, fluvastatin, atorvastatin and rosuvastatin) differ in many of their pharmacologic properties. In addition to lowering LDL-C, statins also increase HDL-cholesterol (HDL-C) moderately. There have been rare reports of significant HDL-C decreases in patients commenced on fibrates and when thiazolidinediones are added to fibrates. This is known as a ‘paradoxical HDL-C decrease’ as both groups of agents usually increase HDL-C. This phenomenon has never been clearly documented following statin therapy. We now describe a patient with type 2 diabetes who showed this paradoxical fall in HDL-C (baseli...

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model [Developmental Biology]

Proceedings of the National Academy of Sciences — Tue, 25 Jan 2011 00:00:00 +0100

Preeclampsia is a relatively common pregnancy-related disorder. Both maternal and fetal lives will be endangered if it proceeds unabated. Recently, the placenta-derived anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFLT1) and soluble endoglin (sENG), have attracted attention in the progression of preeclampsia. Here, we established a unique experimental model to test the role of sFLT1 in preeclampsia using a lentiviral vector-mediated placenta-specific expression system. The model mice showed hypertension and proteinuria during pregnancy, and the symptoms regressed after parturition. Intrauterine growth restriction was also observed. We further showed that pravastatin induced the VEGF-like angiogenic factor placental growth factor (PGF) and ameliorated the symptoms. W...

Monitoring cholesterol levels only modestly effective for detecting adherence to lipid lowering drugs

NeLM - News — Mon, 24 Jan 2011 00:00:00 +0100

Source: BMJ Area: News Analysis of data from the LIPID controlled trial of pravastatin indicates that cholesterol level changes are only modestly useful in detecting non-adherence to treatment and have a poor ability to detect partial adherence. Non-adherence to statin treatment is common, especially in primary prevention: estimates suggest that approaching half of patients started on a statin for primary prevention will have stopped it after two years. Major guidelines suggest using cholesterol level measurement to monitor adherence, however the value of this is unproven. The authors of this paper used data from a large placebo-controlled trial of pravastatin to assess how effectively measuring total and LDL-cholesterol indicated adherence. Participants were 9,014 patients wit...

European CHMP adopts positive opinion on marketing application for Pravafenix (fenofibrate/pravastatin)

NeLM - News — Fri, 21 Jan 2011 00:00:00 +0100

Source: European Medicines Agency (EMA) Area: News The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorisation for Pravafenix (fenofibrate/pravastatin) for the treatment adult patients at high risk of coronary heart disease with mixed dyslipidaemia. (Source: NeLM - News)

Reply to the Editor

The Journal of Thoracic and Cardiovascular Surgery — Thu, 20 Jan 2011 00:48:42 +0100

We appreciate the interest in our work and are pleased to address the aroused considerations. First, we use cisatracurium, and not suxamethonium, as a muscle relaxant. We do not use aminocaproic acid or tranexamic acid, which is why these drugs are not mentioned in our article. Amiodarone, which is known to play a role in rhabdomyolysis development, was entered in the multivariable correction, but no statistically significant correlation was found (P = .75). Unfortunately, we could not retrieve information on the different types of statins that patients were taking because there were several and it was a retrospective study; however, we do know that atorvastatin, simvastatin, rosuvastatin, fluvastatin, and pravastatin were used. Nevertheless, consistent with the latest guidelines, statin ...

Statin benefit for low risk people 'questionable'

NHS News Feed — Wed, 19 Jan 2011 10:49:00 +0100

Conclusion This review examined the use of a statin for primary prevention in people who have not yet suffered a cardiovascular event, and whose risk of having one varied considerably. It is important to point out that the benefit of statins in people with established cardiovascular disease and who have already suffered a heart attack or stroke, or who are considered to be at high risk of suffering a cardiovascular event, is not in question. In high-risk populations, the benefits of a drug that prevents disease often clearly outweigh the risks (such as side effects on health and quality of life). However, in lower-risk populations, this balance often begins to tip the other way and the size of the drug’s benefits compared to its harms can become negligible. This is particularly the case ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Cerebral Microbleeds Are Predictive of Mortality in the Elderly.

Stroke — Thu, 13 Jan 2011 00:00:00 +0100

CONCLUSIONS: This is the first study investigating the association between microbleeds and risk of overall, cardiovascular-related, and stroke-related mortality in an elderly population. Our findings indicate that the diagnosis of microbleeds is potentially of clinical relevance. Larger studies are needed to expand our observations and to address potential clinical implications and cost-benefits of such a policy. PMID: 21233474 [PubMed - as supplied by publisher] (Source: Stroke)

Rosuvastatin Beats Pravastatin for Lipid-Lowering in HIV

Medscape Hiv-Aids Headlines — Thu, 06 Jan 2011 22:30:40 +0100

In HIV patients with hyperlipidemia, rosuvastatin is far more effective than pravastatin - and guidelines should be updated to reflect that, the authors of a new paper suggest. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)

Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin

Atherosclerosis — Thu, 06 Jan 2011 00:00:00 +0100

Conclusion: In men with proven coronary artery disease, MBL2 secretor haplotypes are not associated to the rate of progression of coronary sclerosis nor does pravastatin treatment influence progression based on MBL2 haplotypes. (Source: Atherosclerosis)

Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study.

Clinical Therapeutics — Sat, 01 Jan 2011 00:00:00 +0100

This study was designed to obtain regulatory approval of a fenofibrate/pravastatin 160/40 mg fixed-dose combination (FDC) capsule. PMID: 21397769 [PubMed - in process] (Source: Clinical Therapeutics)